Agenus Inc. (AGEN)
| Market Cap | 359.71M +170.1% |
| Revenue (ttm) | 132.69M +30.5% |
| Net Income | 91.80M |
| EPS | 2.51 |
| Shares Out | 45.02M |
| PE Ratio | 3.19 |
| Forward PE | 36.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 676,565 |
| Open | 7.56 |
| Previous Close | 7.61 |
| Day's Range | 7.54 - 8.00 |
| 52-Week Range | 2.71 - 8.85 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 19.50 (+144.06%) |
| Earnings Date | Aug 6, 2026 |
About AGEN
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte ... [Read more]
Financial Performance
In 2025, Agenus's revenue was $114.20 million, an increase of 10.37% compared to the previous year's $103.46 million. Losses were -$101,000, -99.96% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AGEN stock is "Strong Buy." The 12-month stock price target is $19.5, which is an increase of 144.06% from the latest price.
News
Agenus to Participate in Upcoming September Investor Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen...
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled ...
Agenus: No colorectal cancer recurrences observed at updated follow-up in trial
Agenus (AGEN) announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab, Agenus’ multifunctional, Fc-enhanced an...
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investig...
Agenus price target lowered to $25 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Agenus (AGEN) to $25 from $30 and keeps a Buy rating on the shares. The firm assumes the company will issue 23M…
Agenus files to sell 77.98M shares of common stock for holders
16:04 EDT Agenus (AGEN) files to sell 77.98M shares of common stock for holders
Agenus Registration statement: Registration filing
Agenus filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Agenus Earnings release: Q2 2026
Agenus released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Agenus Quarterly report: Q2 2026
Agenus has published its Q2 2026 quarterly earnings report on August 6, 2026.
Agenus concentrates resources on ROBBIN, discontinues commitment to BATTMAN
Agenus (AGEN) broadened authorized access to BOT+BAL during the second quarter through France’s national Autorisation d’Acces Compassionnel program and physician-led paid named-patient programs in add...
Agenus reports Q2 revenue $34.5M vs $25.7M last year
“The financing completed in July gives us a clear path to act on the clinical evidence supporting BOT+BAL in a large, underserved patient population,” said Garo H. Armen, Ph.D., Chairman…
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the second quarter ended June 30, 2026, and p...
Agenus Slides: Corporate presentation
Agenus has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Agenus price target raised to $14 from $8 at B. Riley
B. Riley analyst Mayank Mamtani raised the firm’s price target on Agenus (AGEN) to $14 from $8 and keeps a Buy rating on the shares.
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2026 financial results before th...
Agenus Registration statement: Registration filing
Agenus filed a registration statement on July 20, 2026, providing details about a securities offering with the SEC.
Agenus files to sell 2.13M shares of common stock for holders
06:05 EDT Agenus (AGEN) files to sell 2.13M shares of common stock for holders
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials e...
Why Is Agenus (AGEN) Stock Up Today?
Agenus stock was up on Monday alongside a new funding announcement and a price target increase.
Agenus price target raised to $30 from $23 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Agenus (AGEN) to $30 from $23 and keeps a Buy rating on the shares. The company announced a strategic…
Agenus announces strategic prioritization of neoadjuvant BOT+BAL
Agenus (AGEN) announced earlier that across NEST and UNICORN, two independent Phase 2 studies evaluating neoadjuvant BOT+BAL in MSS colorectal cancer, BOT+BAL has produced deep, durable responses, inc...
Agenus Transcript: Investor update
A major strategic shift prioritizes the neoadjuvant BOT/BAL program for MSS colon cancer, backed by strong phase II data and FDA-aligned phase III trial design. Up to $340 million in financing secures operations through 2031, targeting a large, underserved market with significant clinical and commercial potential.
Agenus Press release: Investor update
Agenus issued a press release on July 13, 2026, disclosing material business information to investors.
Agenus Slides: Investor update
Agenus has posted slides in relation to its latest quarterly earnings report, which was published on July 13, 2026.
Agenus announces $340M private placement
Agenus (AGEN) announced that it has entered into a securities purchase agreement for a private placement of approximately $85M in upfront gross proceeds, before the deduction of private placement expe...